Phenylbutyrate Metabolite Analysis - Plasma

Clinical Use

Use

This assay measures the levels of phenylacetylglutamine (PAG) and its upstream metabolites phenylbutyrate and phenylacetate in plasma. A hallmark of most urea cycle disorders (UCDs) is the toxic accumulation of ammonia that ultimately leads to several clinical features, including cognitive impairment. Accordingly, treatment for UCD patients involves daily oral intake of ammonia scavenging drugs, including sodium phenylbutyrate (SPB) and/or glycerol phenylbutyrate (GPB). Once consumed, both SPB and GPB are converted to phenylacetate, a compound that scavenges ammonia through the formation of PAG. The key to successful treatment of UCDs is the accurate monitoring of patient compliance and ammonia removal. Unfortunately, daily plasma ammonia levels can fluctuate significantly, making them an inexact diagnostic value. Therefore, the urinary excretion of PAG has been proposed as a dosing biomarker, based on the strong correlation between its levels and daily intake of phenylbutyrate.

Special Instructions

Patient should be treated with oral ammonia scavenging drugs such as sodium phenylbutyrate. The plasma sample should be drawn in a sodium heparin tube and separated as soon as possible to ensure accurate measurement of metabolites. For optimal results, samples should be shipped frozen on dry ice to ensure specimen integrity.

Limitations

This assay may have limitations due to the variability in the plasma ammonia levels of patients, which can fluctuate by as much as tenfold even under optimal conditions. The test results may be influenced by various factors including sample handling and storage conditions. The assessment of plasma metabolite levels may not provide a complete overview of the patient’s condition and should be interpreted in conjunction with clinical findings and other assessments.

Test Details